Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a hypothetical combination vaccine that would include protection against diphtheria, tetanus, acellular pertussis (whooping cough), poliovirus, measles, mumps, rubella (MMR), and varicella (chickenpox). Each component targets a different infectious disease: - Diphtheria and tetanus toxoids are inactivated toxins that stimulate immunity to diphtheria and tetanus. - Acellular pertussis contains purified components of the Bordetella pertussis bacterium to induce immunity against whooping cough. - Poliovirus vaccine is typically an inactivated virus preparation for polio prevention. - MMR combines live attenuated viruses for measles, mumps, and rubella. - Varicella virus vaccine uses a live attenuated strain to protect against chickenpox. Currently available vaccines combine some of these antigens—such as DTaP-IPV (diphtheria-tetanus-acellular pertussis-inactivated polio) or MMRV (measles-mumps-rubella-varicella)—but no single licensed product combines all these components into one shot[1][2][4]. Such a combination would further reduce the number of injections required for full pediatric immunization coverage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphtheria and tetanus toxoids and acellular pertussis + poliovirus + mmr + varicella virus.